Seeing Machines' visual analyser:
This article was originally published in Clinica
Executive Summary
Imaging software firm Seeing Machines, of Canberra, Australia, has received 510(k) marketing clearance from the US FDA for its revolutionary new medical device, the TrueField Analyzer (TFA). The TFA aids the measurement of defects in a patient's visual field, a crucial step in the detection and management of diseases of the vision system, including glaucoma, age related macular degeneration and diabetic retinopathy. The device measures both eyes simultaneously, and the entire test of both eyes can be completed in around five minutes, including rest breaks within the test. US launch of the tool is expected later this year - Seeing Machines intends to exhibit the device at the upcoming annual meeting of the American Academy of Ophthalmology in New Orleans in November. The company received a grant of Aus$113,000 (US$90,376) from the Australian government in June 2006 to fund development of the device (see Clinica No 1209, p 12).
You may also be interested in...
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.